Press Releases

OncoMed Pharmaceuticals SVP/CFO provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs 

New "Grow It Here, Make It Here" legislation introduced today by Sen. Debbie Stabenow (D-Mich.) would help bio-based manufacturers access vital capital, strengthen market opportunities for biobased products, and spur commercialization of agricultural and industrial biotech innovations.

The Biotechnology Industry Organization (BIO) announced today that it has integrated its alliance development activities into one department as a means of expanding engagement opportunities with external groups that share a commitment to unleashing biotechnology’s capability to benefit patients and consumers.

Member companies of three leading advanced and cellulosic biofuel trade organizations sent a letter to House and Senate leaders asking for extension of the Cellulosic Biofuels Production Tax Credit, which expires December 31, 2012.

Continued commercialization of the industrial biotechnology sector can drive the creation of a biobased economy, which can strengthen the nation’s economic security and enhance energy security. 

BIO thanks Sen. Debbie Stabenow (D-Mich.) for announcing policy proposals in Detroit that will spur commercialization of new agricultural innovations, increase access to capital and create a new tax cut for biobased manufacturers.

BIO submitted a letter to EPA asking that they reject a retroactive reduction of the 2011 Renewable Fuel Standard obligations, requested in January by petroleum refiners.

Company executives, scientists and government officials will bring a global perspective as featured presenters at BIO’s 9th annual World Congress on Biotechnology and Bioprocessing. 

Feb 15 2012

The bill will modernize the FDA and accelerate patient access to cures and new treatments.

“The biotechnology industry has long been an engine for economic development and job creation across the country and our sector is working to add more high-wage high-skilled jobs to our workforce." 

“We are excited to bring this conference to Orlando to highlight the industry's growth, the importance of this industrial and environmental biotechnology for generating green jobs, making greener products and cleaner processes all aimed at building a biobased economy." 

BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.

Because of their tremendous environmental and economic benefits, farmers around the world continue to adopt genetically engineered (GE) crops according to a report released today by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). 

Feb 1 2012

In the testimony, Richard Pops, Alkermes plc Chairman and CEO,  stressed the need for a quick reauthorization of the Prescription Drug User Fee Act (PDUFA) and enactment of the enhancements recommended in the PDUFA V agreement. 

Jan 31 2012

The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference.

The USDA's loan guarantee program is helping advanced biofuel companies attract necessary financing for commercial projects. Projects like ZeaChem's can bring jobs and economic growth to rural areas.

BIO calls on the administration and Congress to embrace proposals to Unleash the Promise of Biotechnology.

The 2012 BIO International Convention will feature a program packed with more than 125 breakout sessions.

Biotech company Novozymes provides technology necessary for progress in commercializing advanced biofuels. 

Fireside Chats to focus on biopharma R&D and corporate strategy.

Bittenbender will spearhead BIO’s engagement in and support of state-level legislative and regulatory issues while promoting the responsible development of the bioscience industry and better understanding of policy issues critical to the industry.

BIO strongly supports the PDUFA V recommendations as they will enhance the drug development and review process through increased transparency and scientific dialogue, advance regulatory science, and strengthen post-market surveillance.